Stay updated on LAVA-051 in Relapsed/Refractory Hematologic Malignancies Clinical Trial
Sign up to get notified when there's something new on the LAVA-051 in Relapsed/Refractory Hematologic Malignancies Clinical Trial page.

Latest updates to the LAVA-051 in Relapsed/Refractory Hematologic Malignancies Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedRevision: v3.4.2 has been added. The funding-lapse notice and the prior Revision: v3.4.1 have been removed.SummaryDifference0.4%

- Check20 days agoChange DetectedA site-wide notice about a lapse in government funding and the NIH Clinical Center's status was added, with guidance to refer to opm.gov for updates; the page revision label was updated from v3.4.0 to v3.4.1; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check28 days agoChange DetectedGlossary toggle added; capitalization adjusted for labels (e.g., ‘Last Update Submitted that Met QC Criteria’ and ‘No FEAR Act Data’); revision updated to v3.4.0.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision: v3.3.4 was added and Revision: v3.3.3 was removed; the visible trial details remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check63 days agoChange DetectedLocations section updated: site listings were adjusted (Georgia, New York, North Carolina, Ohio, Texas, North Holland, South Holland) and the page revision updated from v3.3.2 to v3.3.3.SummaryDifference0.8%

- Check85 days agoChange DetectedThe page shows Revision: v3.3.2, replacing v3.3.1, indicating a minor site update with no changes to study content or the user-facing information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to LAVA-051 in Relapsed/Refractory Hematologic Malignancies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the LAVA-051 in Relapsed/Refractory Hematologic Malignancies Clinical Trial page.